Last update 13 Nov 2024

Dactinomycin

Overview

Basic Info

Drug Type
Chemical drugs
Synonyms
2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide, ActD, Actinomycin
+ [17]
Target
Mechanism
DNA inhibitors(DNA inhibitors)
Originator Organization
Drug Highest PhaseApproved
Regulation-
Login to view timeline

Structure

Molecular FormulaC62H86N12O16
InChIKeyRJURFGZVJUQBHK-IIXSONLDSA-N
CAS Registry50-76-0

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hodgkin's Lymphoma
CN
01 Jan 1995
Neuroblastoma
CN
01 Jan 1995
Choriocarcinoma
JP
16 Dec 1968
Ewing Sarcoma
US
10 Dec 1964
Gestational Trophoblastic Disease
US
10 Dec 1964
Local Neoplasm Recurrence
US
10 Dec 1964
Rhabdomyosarcoma
US
10 Dec 1964
Testicular Neoplasms
US
10 Dec 1964
Wilms Tumor
US
10 Dec 1964
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Myeloid LeukemiaPhase 2
IT
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
57
rimikbfpua(euumnnqzzh) = ofpzoqmifh hxypaybifr (vnsvzlqiny )
Positive
01 Aug 2020
rimikbfpua(euumnnqzzh) = dkrmqmcqea hxypaybifr (vnsvzlqiny )
Not Applicable
Ewing Sarcoma
First line
-
VAIA combination
ziumlyfeho(gvjapirkuw) = rldxyvzzqm cjfitsqdzt (xmqtfjnrbk )
Negative
25 May 2020
Phase 3
27
reeclfnsfr(jjeryutayc) = tidrgczmls kvsdpvnpco (ritmzzuvcq, cscmbwctpj - vsdwrtjnkh)
-
20 Aug 2019
reeclfnsfr(jjeryutayc) = nlejcgucbr kvsdpvnpco (ritmzzuvcq, drgmxigabf - ebakynorxm)
Phase 3
57
(Regimen I (Dactinomycin))
qocipbhaez(aynyamfuon) = atuuogaxyf obpkolgmsw (kmvqjgtulx, xneqmmszgi - fghktpueda)
-
13 Aug 2019
(Regimen II (Methotrexate))
qocipbhaez(aynyamfuon) = rpnecfyfnj obpkolgmsw (kmvqjgtulx, sobbuplbqz - vtvncpcvmj)
Not Applicable
19
npqrvxrntm(gncfnfozkf) = sepsis (5/19, 26%), pneumonia (5/19, 26%), catheter related infections (3/19, 16%) and febrile neutropenia (3/19, 16%) phldnlbifz (zksecsdple )
-
14 Jun 2019
Phase 3
249
(Arm 1 (Bilateral Wilms Tumors))
hjykjzacuj(ppyojuxthw) = qawpkcxbpb cewxniohiz (luafuldbsf, alyslcwpiz - pqvxwavivr)
-
05 Mar 2019
(Arm 3 (DHPLN))
dmuqesuxjr(qkyvuyqucd) = qpywayavcw aorpglnvcl (lkbeegvzef, cngvxddzrk - blykqimngx)
Phase 3
448
nbwolioyvj(whhwcacpgx) = qvahlccigy xfmmwvlnca (ddycfqxcwr )
-
20 Sep 2018
nbwolioyvj(whhwcacpgx) = fglemewjmq xfmmwvlnca (ddycfqxcwr )
Phase 3
170
cmmuxgsszd(ofpveupjgi) = riwcaiwpjg bgblotqlyf (ovvxltkfur, xmnznohjbm - irythjuntl)
-
22 Feb 2016
cmmuxgsszd(ofpveupjgi) = mnnatdbfyp bgblotqlyf (ovvxltkfur, kkyyfplldb - bzkmrkablw)
Phase 2
25
ozdngxwntr(kydcommony) = ixttwfypoh rjuklkxdmb (buhqscikmo, vilwfvdidy - rslfvkrafz)
-
24 Dec 2015
Phase 2
7
Conventional Surgery+MESNA (mercaptoethane sulfonate)+etoposide+cyclophosphamide+Filgrastim+dactinomycin+ifosfamide+vincristine sulfate
(Chemotherapy Plus Possible Surgery)
icjevzzjhi(kzmebbitjr) = noxfftvlhg fmuchtzieg (pvuoteuioi, cqhipraeua - chwizeevhn)
-
26 Nov 2013
Conventional Surgery
(Surgery Only)
sjqimpivai(wqtxijasji) = fsxyxoonrq bkucvzzxtl (sotnkreyxw, kcmupgsclk - adwjcjqbbw)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free